Imaging the heart and kidneys in people with chronic kidney disease
Uses PET/MR scans to study heart function and scarring in chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective
Key facts
- Where
- Qingdao, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease (CKD) who can have a heart scan with 18F-FAPI PET/MR imaging. It studies how kidney function and the heart affect each other.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease diagnosed by KDIGO guidelines. Group I is stages 1-3 (eGFR ≥ 30 mL/min/1.73 m²). Group II is stages 4-5 (eGFR < 30 mL/min/1.73 m²).
Main reasons for not taking part
- Pregnant, planning pregnancy, or breastfeeding
- Cannot have PET/MR imaging (for example metal implants or claustrophobia)
- Allergy to gadolinium-based contrast agents
- Malignant tumor or other serious progressive disease
- Severe heart disease, such as advanced heart failure, or unstable circulation
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07107919, who can take part
Where in China
- The Affiliated Hospital of Qingdao UniversityQingdao, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- The Affiliated Hospital of Qingdao University
- Trial code
- NCT07107919
- Record updated
- 6 August 2025
- Original description
This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR < 30 mL/min/1.73 m²).Read full original descriptionShow less
Multimodal Imaging Assessment of Chronic Kidney Disease Patients at Different Stages From a Cardio-Renal Interaction Perspective
This study is a prospective cohort investigation in which consecutive eligible patients undergo 18F-FAPI PET/MR imaging. Chronic kidney disease (CKD) participants are stratified into two groups:Group I ：CKD stages 1-3（eGFR ≥ 30 mL/min/1.73 m²）,Group II :CKD stages 4-5(eGFR < 30 mL/min/1.73 m²).
Using 18F-FAPI PET/MR, we will evaluate global cardiac functional impairment and myocardial fibrosis characteristics, and analyze their associations with the degree of renal dysfunction.
Inclusion: Age between 18 and 80 years, regardless of sex; Clinically diagnosed with chronic kidney disease (CKD), based on KDIGO guidelines; Complete clinical data available; Written informed consent for participation and for undergoing 18F-FAPI PET/MR imaging is obtained from the patient or their legal guardian; Female participants must agree to use effective contraception during the study and for at least 6 months after its completion (e.g., sterilization, intrauterine hormonal devices, condoms, hormonal contraceptives, abstinence, or vasectomized partner). Male participants must also agree to use contraception during the study and for 6 months after its completion.
Exclusion: Contraindications to PET/MR imaging, including but not limited to metal implants, claustrophobia, or inability to tolerate cardiac MRI due to respiratory difficulties; History of allergy or hypersensitivity to gadolinium-based contrast agents; Presence of malignant tumors or other serious progressive diseases; Patients with severe cardiac conditions, such as advanced heart failure, severe valvular disease, or cardiomyopathies; Presence of severe systemic or localized infections, or other serious comorbid conditions; Women who are planning to conceive, currently pregnant, or breastfeeding; Hemodynamic instability; Incomplete clinical data; Any other reason deemed by the investigators to make the subject unsuitable for participation, including inability or unwillingness to comply with study procedures and requirements; Determined by the investigators to be inappropriate for inclusion in the study.